Template:BerkiGEM2007 WikiPlaying
From 2007.igem.org
(Difference between revisions)
| Line 122: | Line 122: | ||
position:absolute; | position:absolute; | ||
left:0px; | left:0px; | ||
| - | top: | + | top:154px; |
width:850px; | width:850px; | ||
height:50px; | height:50px; | ||
| Line 376: | Line 376: | ||
height:27px; | height:27px; | ||
z-index:30; | z-index:30; | ||
| + | } | ||
| + | #apDiv35 { | ||
| + | position:absolute; | ||
| + | left:9px; | ||
| + | top:194px; | ||
| + | width:871px; | ||
| + | height:130px; | ||
| + | z-index:41; | ||
} | } | ||
--> | --> | ||
| Line 388: | Line 396: | ||
<p>Bottom of the Logo</p> | <p>Bottom of the Logo</p> | ||
</div> | </div> | ||
| - | <div id="apDiv3">Text in the bottom div | + | <div id="apDiv3">Text in the bottom div</div> |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | </div> | + | |
| Line 442: | Line 441: | ||
<div id="apDiv33"><img name="ControllerMenu" src="https://static.igem.org/mediawiki/2007/2/2a/LargeUnexpandedMenuButton.jpg" width="155" height="40" alt=""></div> | <div id="apDiv33"><img name="ControllerMenu" src="https://static.igem.org/mediawiki/2007/2/2a/LargeUnexpandedMenuButton.jpg" width="155" height="40" alt=""></div> | ||
<div id="apDiv34"><img name="StorageMenu" src="https://static.igem.org/mediawiki/2007/2/2a/LargeUnexpandedMenuButton.jpg" width="155" height="40" alt=""></div> | <div id="apDiv34"><img name="StorageMenu" src="https://static.igem.org/mediawiki/2007/2/2a/LargeUnexpandedMenuButton.jpg" width="155" height="40" alt=""></div> | ||
| + | <div id="apDiv35"><strong>The global demand and importance</strong> for cheap, available, and disease free blood substitutes is undisputed. There are currently no red blood cell substitutes approved for clinical use in the US or the UK, and whole blood is almost always in short supply. Underdeveloped countries that need blood the most simply don’t have the infrastructure to support donation and storage, in addition a sizeable fraction of the population are disease carriers. We are developing an innovative and cheap blood substitute based on engineered <em>E. coli</em> with all the critical properties of human erythrocytes. These include the ability to safely exist in the bloodstream, carry oxygen, and be stored for prolonged periods in a freeze-dried state.</div> | ||
<div> | <div> | ||
<p> </p> | <p> </p> | ||
| Line 449: | Line 449: | ||
<p> </p> | <p> </p> | ||
<p> </p> | <p> </p> | ||
| - | |||
<p> </p> | <p> </p> | ||
<p> </p> | <p> </p> | ||
Revision as of 06:28, 7 October 2007
Text in the logo
Bottom of the Logo
Text in the bottom div
Oxygen Transport
Immunity
Storage
System Controller
Kill Switch
Antioxidants
Growth Control
Oxygen Transport
Antiodixants
Immunity
Growth Control
System Controller
Storage
The global demand and importance for cheap, available, and disease free blood substitutes is undisputed. There are currently no red blood cell substitutes approved for clinical use in the US or the UK, and whole blood is almost always in short supply. Underdeveloped countries that need blood the most simply don’t have the infrastructure to support donation and storage, in addition a sizeable fraction of the population are disease carriers. We are developing an innovative and cheap blood substitute based on engineered E. coli with all the critical properties of human erythrocytes. These include the ability to safely exist in the bloodstream, carry oxygen, and be stored for prolonged periods in a freeze-dried state.
